Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Thin Film Drugs Market by Product (Oral Thin Film, Transdermal Thin Film) and by Disease Indication (Schizophrenia, Migraine, Opioid Dependence, Nausea and Vomiting, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03780

Pages: NA

Charts: NA

Tables: NA

Thin film drugs have emerged as an alternative to tablets or capsules due to its effective therapeutic results. The drugs are made of polymers that rapidly dissolve when kept in the mouth or buccal cavity, delivering the drug directly to systemic circulation in the body.

The lower manufacturing costs of thin film drugs, increasing demand for effective drug delivery systems, coupled with increasing research to develop newer polymeric thin films are expected to increase the demand for thin film drugs. However, high costs associated with the treatment restrain the market growth. In addition, effective therapeutic output of the drugs when compared to traditional drugs provides a lucrative opportunity for the market to grow.

The global thin film drugs market is segmented based on product, disease indication, and region. On the basis of product, the market is divided into oral thin films, transdermal thin films, and others. Oral thin films are further bifurcated into sublingual film and fully dissolving dental/buccal films. Based on disease indication, it is categorized into schizophrenia, migraine, opioid dependence, nausea & vomiting, and others. By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include Pfizer, Inc., Novartis AG, Wolters Kluwer, Solvay, Allergan plc, Sumitomo Dainippon Pharma Co., Ltd., and IntelGenx Corp.

Key Benefit

  • The study provides an in-depth analysis of the global thin film drugs market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the global thin film drugs market which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the global thin film drugs market has been provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
  • Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the global thin film drugs market.

 Key Market Segments

  • By Product
    • Oral Thin Film
      • Sublingual Film
      • Fully Dissolving Dental or Buccal Film
    • Transdermal Thin Film
  • By Disease Indication
    • Schizophrenia
    • Migraine
    • Opioid Dependence
    • Nausea and Vomiting
    • Others
  • By Region
    • North America
      • UNITED STATES
      • CANADA
      • MEXICO
    • Europe
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • UNITED KINGDOM
      • Rest of Europe
    • Asia-Pacific
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • AUSTRALIA
      • Rest of Asia Pacific
    • LAMEA
      • Brazil
      • South Africa,
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Eli Lilly and Company
  • Novartis AG
  • AstraZeneca plc
  • Celgene Corporation
  • Johnson & Johnson
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Merck & Co.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: THIN FILM DRUGS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Oral Thin Film

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Sublingual Film

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Fully Dissolving Dental or Buccal Film

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Transdermal Thin Film

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: THIN FILM DRUGS MARKET, BY DISEASE INDICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Disease Indication

    • 5.2. Schizophrenia

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Migraine

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Opioid Dependence

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Nausea And Vomiting

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: THIN FILM DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Disease Indication

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Thin Film Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Disease Indication

      • 6.2.6. Canada Thin Film Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Disease Indication

      • 6.2.7. Mexico Thin Film Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Disease Indication

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Disease Indication

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Thin Film Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Disease Indication

      • 6.3.6. Germany Thin Film Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Disease Indication

      • 6.3.7. Italy Thin Film Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Disease Indication

      • 6.3.8. Spain Thin Film Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Disease Indication

      • 6.3.9. UK Thin Film Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Disease Indication

      • 6.3.10. Russia Thin Film Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Disease Indication

      • 6.3.11. Rest Of Europe Thin Film Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Disease Indication

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Disease Indication

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Thin Film Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Disease Indication

      • 6.4.6. Japan Thin Film Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Disease Indication

      • 6.4.7. India Thin Film Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Disease Indication

      • 6.4.8. South Korea Thin Film Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Disease Indication

      • 6.4.9. Australia Thin Film Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Disease Indication

      • 6.4.10. Thailand Thin Film Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Disease Indication

      • 6.4.11. Malaysia Thin Film Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Disease Indication

      • 6.4.12. Indonesia Thin Film Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Disease Indication

      • 6.4.13. Rest of Asia Pacific Thin Film Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Disease Indication

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Disease Indication

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Thin Film Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Disease Indication

      • 6.5.6. South Africa Thin Film Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Disease Indication

      • 6.5.7. Saudi Arabia Thin Film Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Disease Indication

      • 6.5.8. UAE Thin Film Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Disease Indication

      • 6.5.9. Argentina Thin Film Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Disease Indication

      • 6.5.10. Rest of LAMEA Thin Film Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Disease Indication

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Novartis AG

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Merck And Co.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Eli Lilly And Company

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Pfizer Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. AbbVie Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Johnson And Johnson

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Sanofi S.A.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Celgene Corporation

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. GlaxoSmithKline Plc

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. AstraZeneca Plc

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL THIN FILM DRUGS MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL THIN FILM DRUGS MARKET FOR ORAL THIN FILM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL THIN FILM DRUGS MARKET FOR TRANSDERMAL THIN FILM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL THIN FILM DRUGS MARKET, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL THIN FILM DRUGS MARKET FOR SCHIZOPHRENIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL THIN FILM DRUGS MARKET FOR MIGRAINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL THIN FILM DRUGS MARKET FOR OPIOID DEPENDENCE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL THIN FILM DRUGS MARKET FOR NAUSEA AND VOMITING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL THIN FILM DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL THIN FILM DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA THIN FILM DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 14. U.S. THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 15. U.S. THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 16. CANADA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 17. CANADA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE THIN FILM DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 27. ITALY THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 28. ITALY THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 31. UK THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 32. UK THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC THIN FILM DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 40. CHINA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. CHINA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 44. INDIA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 45. INDIA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA THIN FILM DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 67. UAE THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 68. UAE THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 73. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 74. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 75. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 76. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 77. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. MERCK AND CO.: KEY EXECUTIVES
  • TABLE 79. MERCK AND CO.: COMPANY SNAPSHOT
  • TABLE 80. MERCK AND CO.: OPERATING SEGMENTS
  • TABLE 81. MERCK AND CO.: PRODUCT PORTFOLIO
  • TABLE 82. MERCK AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 84. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 85. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 86. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 87. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. PFIZER INC.: KEY EXECUTIVES
  • TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 90. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 92. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 94. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 95. ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 96. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 97. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 99. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 100. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 101. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 102. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 104. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 105. SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 106. SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 107. SANOFI S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. CELGENE CORPORATION: KEY EXECUTIVES
  • TABLE 109. CELGENE CORPORATION: COMPANY SNAPSHOT
  • TABLE 110. CELGENE CORPORATION: OPERATING SEGMENTS
  • TABLE 111. CELGENE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 112. CELGENE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 114. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 115. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 116. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 117. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 119. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 120. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 121. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 122. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL THIN FILM DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL THIN FILM DRUGS MARKET
  • FIGURE 3. SEGMENTATION THIN FILM DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN THIN FILM DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTHIN FILM DRUGS MARKET
  • FIGURE 11. THIN FILM DRUGS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. THIN FILM DRUGS MARKET FOR ORAL THIN FILM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. THIN FILM DRUGS MARKET FOR TRANSDERMAL THIN FILM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. THIN FILM DRUGS MARKET SEGMENTATION, BY BY DISEASE INDICATION
  • FIGURE 15. THIN FILM DRUGS MARKET FOR SCHIZOPHRENIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. THIN FILM DRUGS MARKET FOR MIGRAINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. THIN FILM DRUGS MARKET FOR OPIOID DEPENDENCE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. THIN FILM DRUGS MARKET FOR NAUSEA AND VOMITING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. THIN FILM DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: THIN FILM DRUGS MARKET
  • FIGURE 26. TOP PLAYER POSITIONING, 2024
  • FIGURE 27. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. MERCK AND CO.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. MERCK AND CO.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. MERCK AND CO.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. ELI LILLY AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. ABBVIE INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. ABBVIE INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. SANOFI S.A.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. SANOFI S.A.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. SANOFI S.A.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. CELGENE CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. CELGENE CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. CELGENE CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. GLAXOSMITHKLINE PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. ASTRAZENECA PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Thin Film Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved